AR094053A1 - Derivados de indol carboxamida como antagonistas del receptor p2x₇ - Google Patents
Derivados de indol carboxamida como antagonistas del receptor p2x₇Info
- Publication number
- AR094053A1 AR094053A1 ARP130104786A ARP130104786A AR094053A1 AR 094053 A1 AR094053 A1 AR 094053A1 AR P130104786 A ARP130104786 A AR P130104786A AR P130104786 A ARP130104786 A AR P130104786A AR 094053 A1 AR094053 A1 AR 094053A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- represents hydrogen
- hydroxy
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1), en donde n representa 1, 2, 3 ó 4; R¹ representa hidrógeno y R² representa hidroxi; hidroxi-alquilo C₁₋₃; alcoxi C₁₋₃; -NHR¹¹; -N(CH₃)₂; -CN; -CONH₂; alcoxi C₁₋₄-carbonilo; alquilamino C₁₋₄-carbonilo; arilo que es insustituido o mono- o di-sustituido con fluoroalquilo C₁₋₃ o halógeno; o heteroarilo que es insustituido o mono- o di-sustituido con alquilo C₁₋₄, fluoroalquilo C₁₋₃ o halógeno; o R¹ representa alquilo C₁₋₃ o hidroxi-alquilo C₁₋₃ y R² representa hidrógeno; R³ representa hidrógeno o fluoro; R⁴ representa hidrógeno o fluoro; R⁵ representa hidrógeno, alquilo C₁₋₄ o halógeno; R⁶ representa hidrógeno, alquilo C₁₋₄, alcoxi C₁₋₄, alquil C₁₋₄-carbonilo, hidroxi-alquil C₁₋₄, hidroxi-alcoxi C₂₋₄, alcoxi C₁₋₂-alquilo C₁₋₄, alcoxi C₁₋₄-alcoxi C₂₋₄, hidroxi, amino, nitro o halógeno; R⁷ representa hidrógeno o alquilo C₁₋₃; R⁸ representa hidrógeno, alquilo C₁₋₄ o hidroxi; R⁹ representa hidrógeno, alquilo C₁₋₄, alquiltio C₁₋₄, formilo o halógeno; R¹⁰ representa fluoro, cloro, metilo, etilo, fluoroalquilo C₁₋₂ o metoxi; y R¹¹ representa hidrógeno, bencilo, alquil C₁₋₄-carbonilo, alcoxi C₁₋₄-carbonilo o alquil C₁₋₄-sulfonilo que es insustituido o mono-sustituido con hidroxi o alcoxi C₁₋₄-carbonilo; o una sal de dicho compuesto.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12197880 | 2012-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR094053A1 true AR094053A1 (es) | 2015-07-08 |
Family
ID=47358029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130104786A AR094053A1 (es) | 2012-12-18 | 2013-12-17 | Derivados de indol carboxamida como antagonistas del receptor p2x₇ |
Country Status (10)
Country | Link |
---|---|
US (1) | US9556117B2 (es) |
EP (1) | EP2935211B1 (es) |
JP (1) | JP6295270B2 (es) |
KR (1) | KR102232744B1 (es) |
CN (1) | CN104854087B (es) |
AR (1) | AR094053A1 (es) |
CA (1) | CA2891499C (es) |
ES (1) | ES2614495T3 (es) |
TW (1) | TW201427945A (es) |
WO (1) | WO2014097140A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2014000894A (es) | 2011-07-22 | 2014-02-27 | Actelion Pharmaceuticals Ltd | Derivados de amidas heterociclicas como antagonistas de receptores p2x7. |
EA024204B1 (ru) | 2012-01-20 | 2016-08-31 | Актелион Фармасьютиклз Лтд. | Производные гетероциклических амидов в качестве антагонистов p2xрецептора |
WO2014091415A1 (en) | 2012-12-12 | 2014-06-19 | Actelion Pharmaceuticals Ltd | Indole carboxamide derivatives as p2x7 receptor antagonists |
CN104918617B (zh) | 2013-01-22 | 2017-05-10 | 埃科特莱茵药品有限公司 | 作为p2x7受体拮抗剂的杂环酰胺衍生物 |
EP2956457B1 (en) | 2013-01-22 | 2016-11-23 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
CN106187899B (zh) * | 2016-06-28 | 2019-07-16 | 绍兴文理学院 | 一种氟代氮杂芳烃的合成方法 |
FI3609868T3 (fi) * | 2017-03-13 | 2023-11-22 | Raqualia Pharma Inc | Tetrahydrokinoliinijohdannaisia P2X7-reseptorin antagonisteina |
WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
WO2022189636A1 (en) * | 2021-03-12 | 2022-09-15 | Biomedcode Hellas Sa | Anti-inflammatory carboxamide derivatives |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2636341A1 (fr) * | 1988-09-12 | 1990-03-16 | Air Liquide | Procede et installation de recuperation des hydrocarbures les plus lourds d'un melange gazeux |
SE9704544D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
BR0009651A (pt) | 1999-04-09 | 2002-01-08 | Astrazeneca Ab | Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas |
SE9904505D0 (sv) | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
WO2003042190A1 (en) | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
SE0103836D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
TW200307539A (en) * | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
SE0200920D0 (sv) | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
AU2003288640A1 (en) | 2002-12-31 | 2004-07-22 | Pfizer Products Inc. | Benzamide inhibitors of the p2x7 receptor |
PA8591801A1 (es) | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
BRPI0410349A (pt) | 2003-05-12 | 2006-05-30 | Pfizer Prod Inc | inibidores de benzamida do receptor p2x7 |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
SE0302139D0 (sv) | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
SE0302192D0 (sv) | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
WO2005111003A1 (en) | 2004-04-29 | 2005-11-24 | Abbott Laboratories | Amino-tetrazoles analogues and methods of use |
SA05260265A (ar) | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
SE0402925D0 (sv) | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
GB0428232D0 (en) * | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Compounds |
JP2008528580A (ja) | 2005-01-27 | 2008-07-31 | アストラゼネカ・アクチエボラーグ | P2x7受容体の阻害剤である新規二環式芳香族化合物 |
US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
JP4257926B2 (ja) * | 2005-04-19 | 2009-04-30 | 協和発酵キリン株式会社 | 含窒素複素環化合物 |
WO2007055374A1 (ja) | 2005-11-14 | 2007-05-18 | Mitsubishi Tanabe Pharma Corporation | 骨粗鬆症治療剤 |
US20100184802A1 (en) | 2006-03-16 | 2010-07-22 | Kelly Michael G | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof |
TWI464148B (zh) | 2006-03-16 | 2014-12-11 | Evotec Us Inc | 作為p2x7調節劑之雙環雜芳基化合物與其用途 |
EP1937643B1 (en) | 2006-03-16 | 2016-07-13 | Second Genome, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
WO2007109182A2 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
US8546579B2 (en) | 2006-03-16 | 2013-10-01 | Evotec (Us) Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
CA2645652A1 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
US20090149524A1 (en) | 2006-06-06 | 2009-06-11 | Paul John Beswick | N-(Phenylmethyl)-2-(1H-Pyrazol-4-yl) Acetamide Derivatives as P2X7 Antagonists for the Treatment of Pain, Inflammation and Neurodegeneration |
GB0611154D0 (en) | 2006-06-06 | 2006-07-19 | Glaxo Group Ltd | Novel receptor antagonists and their methods of use |
WO2008003697A1 (en) | 2006-07-06 | 2008-01-10 | Glaxo Group Limited | Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use |
ZA200904477B (en) * | 2006-11-27 | 2010-09-29 | Lundbeck & Co As H | Heteroaryl amide derivatives |
CN101686680B (zh) | 2007-03-09 | 2015-12-09 | 伊沃泰克美国股份有限公司 | 作为p2x7调节剂的双环杂芳基化合物及其用途 |
AR065806A1 (es) | 2007-03-22 | 2009-07-01 | Astrazeneca Ab | Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea. |
GB0705882D0 (en) | 2007-03-27 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
WO2008116845A1 (en) | 2007-03-28 | 2008-10-02 | Glaxo Group Limited | Piperidinone carboxamide derivatives as p2x7 modulators |
WO2008119685A2 (en) | 2007-03-29 | 2008-10-09 | Glaxo Group Limited | Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators |
EA200970912A1 (ru) | 2007-04-03 | 2010-02-26 | Глэксо Груп Лимитед | Карбоксамидные производные имидазолидина в качестве модуляторов p2x7 |
EP2592082A1 (en) | 2007-04-10 | 2013-05-15 | H. Lundbeck A/S | Heteroaryl amide analogues as p2x7 antagonists |
US20100056595A1 (en) | 2007-04-11 | 2010-03-04 | Glaxo Group Limited | Pyrazole Derivatives as P2X7 Modulators |
US20110046137A1 (en) | 2007-05-10 | 2011-02-24 | Glaxo Group Limited | Pyrazole Derivatives as P2X7 Modulators |
CN101711245B (zh) | 2007-07-19 | 2015-03-25 | H.隆德贝克有限公司 | 5元杂环酰胺及相关的化合物 |
CN101778850A (zh) * | 2007-08-10 | 2010-07-14 | H.隆德贝克有限公司 | 杂芳基酰胺类似物 |
US8106073B2 (en) | 2007-11-30 | 2012-01-31 | Astrazeneca Ab | Quinoline derivatives 057 |
GB0724258D0 (en) | 2007-12-12 | 2008-01-30 | Glaxo Group Ltd | Novel combinations |
WO2009074518A1 (en) | 2007-12-12 | 2009-06-18 | Glaxo Group Limited | Combinations of prolinamide p2x7 modulators with further therapeutic agents |
JP2011506554A (ja) | 2007-12-18 | 2011-03-03 | グラクソ グループ リミテッド | P2x7調節因子としての5−オキソ−3−ピロリジンカルボキサミド誘導体 |
GB0724625D0 (en) | 2007-12-18 | 2008-01-30 | Glaxo Group Ltd | Novel compounds |
WO2009108551A2 (en) | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
PT2105164E (pt) * | 2008-03-25 | 2011-03-24 | Affectis Pharmaceuticals Ag | Novos antagonistas de p2x7r e a sua utilização |
AU2009239471B2 (en) | 2008-04-22 | 2013-01-24 | Janssen Pharmaceutica Nv | Quinoline or isoquinoline substituted P2X7 antagonists |
PT2565191E (pt) * | 2008-05-14 | 2014-12-04 | Astellas Pharma Inc | Derivados do ácido 4-(indol-7- ilcarbonilaminometil)ciclo-hexanocarboxílico como antagonistas de receptores ep4, úteis no tratamento de insuficiência renal crónica ou de nefropatia diabética |
MX2011004414A (es) * | 2008-10-30 | 2011-06-21 | Oncotherapy Science Inc | Derivados de 7-hidroxi-benzoimidazol-4-il-metanona e inhibidores de cinasa que enlaza pdz que contienen los mismos. |
CN102395562A (zh) | 2009-04-14 | 2012-03-28 | 阿费克蒂斯制药股份公司 | 新的p2x7r拮抗剂及其用途 |
GB0919594D0 (en) | 2009-11-09 | 2009-12-23 | Glaxo Group Ltd | Compounds |
WO2011123719A2 (en) * | 2010-03-31 | 2011-10-06 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating abdominal, visceral and pelvic pain |
US20120157494A1 (en) | 2010-12-16 | 2012-06-21 | Harris Iii Ralph New | Isoindolyl compounds |
WO2012114268A1 (en) * | 2011-02-22 | 2012-08-30 | Actelion Pharmaceuticals Ltd | Benzamide derivatives as p2x7 receptor antagonists |
WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
MX2014000894A (es) | 2011-07-22 | 2014-02-27 | Actelion Pharmaceuticals Ltd | Derivados de amidas heterociclicas como antagonistas de receptores p2x7. |
EA024204B1 (ru) | 2012-01-20 | 2016-08-31 | Актелион Фармасьютиклз Лтд. | Производные гетероциклических амидов в качестве антагонистов p2xрецептора |
TWI598325B (zh) | 2012-10-12 | 2017-09-11 | H 朗德貝克公司 | 苯甲醯胺類 |
TW201427947A (zh) | 2012-10-12 | 2014-07-16 | Lundbeck & Co As H | 環狀胺 |
WO2014091415A1 (en) | 2012-12-12 | 2014-06-19 | Actelion Pharmaceuticals Ltd | Indole carboxamide derivatives as p2x7 receptor antagonists |
EP2956457B1 (en) | 2013-01-22 | 2016-11-23 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
CN104918617B (zh) | 2013-01-22 | 2017-05-10 | 埃科特莱茵药品有限公司 | 作为p2x7受体拮抗剂的杂环酰胺衍生物 |
-
2013
- 2013-12-17 AR ARP130104786A patent/AR094053A1/es unknown
- 2013-12-17 TW TW102146756A patent/TW201427945A/zh unknown
- 2013-12-17 WO PCT/IB2013/061029 patent/WO2014097140A1/en active Application Filing
- 2013-12-17 ES ES13826623.4T patent/ES2614495T3/es active Active
- 2013-12-17 CN CN201380065566.6A patent/CN104854087B/zh not_active Expired - Fee Related
- 2013-12-17 JP JP2015548833A patent/JP6295270B2/ja not_active Expired - Fee Related
- 2013-12-17 EP EP13826623.4A patent/EP2935211B1/en not_active Not-in-force
- 2013-12-17 KR KR1020157019206A patent/KR102232744B1/ko not_active Expired - Fee Related
- 2013-12-17 US US14/653,363 patent/US9556117B2/en not_active Expired - Fee Related
- 2013-12-17 CA CA2891499A patent/CA2891499C/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2014097140A1 (en) | 2014-06-26 |
EP2935211A1 (en) | 2015-10-28 |
CA2891499A1 (en) | 2014-06-26 |
CN104854087B (zh) | 2017-03-22 |
CA2891499C (en) | 2021-07-06 |
JP2016504995A (ja) | 2016-02-18 |
KR102232744B1 (ko) | 2021-03-26 |
US20150344425A1 (en) | 2015-12-03 |
CN104854087A (zh) | 2015-08-19 |
US9556117B2 (en) | 2017-01-31 |
TW201427945A (zh) | 2014-07-16 |
ES2614495T3 (es) | 2017-05-31 |
JP6295270B2 (ja) | 2018-03-14 |
EP2935211B1 (en) | 2016-11-09 |
KR20150095905A (ko) | 2015-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR094053A1 (es) | Derivados de indol carboxamida como antagonistas del receptor p2x₇ | |
AR090967A1 (es) | Picolinamidas macrociclicas como fungicidas | |
AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
MX2017006266A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
AR093921A1 (es) | Derivados de indol carboxamida como antagonistas del receptor p2x7 | |
EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
AR102537A1 (es) | Agentes inmunomoduladores | |
AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
CR20150520A (es) | 4-amino-6-(heterocíclico)picolinatos y 6-amino-amino-2-(heterocíclico) pirimidin -4-carboxilatos y su uso como herbicidas | |
AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
CU20180144A7 (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
AR097279A1 (es) | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
AR099400A1 (es) | Compuesto heterocíclico fusionado | |
AR100058A1 (es) | DERIVADOS DE PIRIMIDIN-PIRAZINAS FUSIONADAS MODULADORES DE RORg | |
AR090966A1 (es) | Picolinamidas macrociclicas como fungicidas | |
AR101367A1 (es) | Pirimidinonas como inhibidores del factor xia | |
AR097866A1 (es) | Derivados de 4-azaindol | |
LT3350163T (lt) | Mono- arba dipakeistieji indolo dariniai kaip dengės viruso replikacijos slopikliai | |
LT3436437T (lt) | Pakeistieji indolo dariniai kaip dengės viruso replikacijos inhibitoriai | |
EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
LT3350162T (lt) | Mono- arba dipakeistieji indolo dariniai kaip dengės viruso replikacijos inhibitoriai | |
AR090670A1 (es) | Compuestos herbicidas | |
AR084173A1 (es) | Derivados oxazolil-metileter como agonistas del receptor alx | |
AR106604A1 (es) | Compuestos de criptoficina y productos conjugados, su preparación y su uso terapéutico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |